NEW YORK, Nov. 7 (GenomeWeb News) - Amersham announced today that Eli Lilly has licensed the rights to Amersham's Aequorea Victoria Green Fluorescent Protein and has secured rights to operate under Biolmage's Redistribution patent portfolio for monitoring intracellular signaling pathways.
Lilly will use the licensed technologies, along with a recently purchased IN Cell Analyzer 3000 high-throughput imaging system from Amersham, to look at drug targets in a biological context, the companies said.
Financial details of the agreement were not disclosed.
